Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma

Cancer Research

Volumn 63, Issue 7, 2003, Pages 1639-1643

  Spugnardi, Mia ^a   Tommasi, Stella ^b   Dammann, Reinhard ^c   Pfeifer, Gerd P ^b   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CHROMOSOME 3P; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; EXON; GENE EXPRESSION; GENE INACTIVATION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MELANOMA CELL; METHYLATION; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BIOPSY; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037380925     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
2. Baylin, S. B., and Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet., 16: 168-174, 2000.
3. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
4. Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.
5. Sidransky, D. Emerging molecular markers of cancer. Nat. Rev. Cancer, 2: 210-219, 2002.
6. Baylin, S., and Bestor, T. H. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cells, 1: 299-305, 2002.
7. Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomaki, P., Lang, J. C., Schuller, D. E., Yu, L., Bloomfield, C. D., Caligiuri, M. A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N. J., Zhang, X., O'Dorisio, M. S., Held, W. A., Cavenee, W. K., and Plass, C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet., 24: 132-138, 2000.
8. Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon-Cardo, C., and Lowe, S. W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (Lond.), 409: 207-211, 2001.
9. Worm, J., Bartkova, J., Kirkin, A. F., Straten, P., Zeuthen, J., Bartek, J., and Guldberg, P. Aberrant p27Kipl promoter methylation in malignant melanoma. Oncogene, 19: 5111-5115, 2000.
10. Fujimoto, A., Morita, R., Hatta, N., Takehara, K., and Takata, M. p161NK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene, 18: 2527-2532, 1999.
11. Merbs, S. L., and Sidransky, D. Analysis of p16 (CDKN2/MTS-1/1NK4A) alterations in primary sporadic uveal melanoma. Investig. Ophthalmol. Vis. Sci., 40: 779-783, 1999.
12. Christmann, M., Pick, M., Lage, H., Schadendorf, D., and Kaina, B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int. J. Cancer, 92: 123-129, 2001.
13. Bar-Sagi, D., and Hall, A. Ras and Rho GTPases: a family reunion. Cell, 103: 227-238, 2000.
14. Katz, M. E., and McCormick, F. Signal transduction from multiple Ras effectors. Curr. Opin. Genet. Dev., 7: 75-79, 1997.
15. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998.
16. Vavvas, D., Li, X., Avruch, J., and Zhang, X. F. Identification of Norel as a potential Ras effector. J. Biol. Chem., 273: 5439-5442, 1998.
17. Ponting, C. P., and Benjamin, D. R. A novel family of Ras-binding domains. Trends Biochem. Sci., 21: 422-425, 1996.
18. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25: 315-319, 2000.
19. Dammann, R., Yang, G., and Pfeifer, G. P. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61: 3105-3109, 2001.
20. Sekido, Y., Ahmadian, M., Wistuba, I. I., Latif, F., Bader, S., Wei, M. H., Duh, F. M., Gazdar, A. F., Lerman, M. I., and Minna, J. D. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene, 16: 3151-3157, 1998.
21. Agathanggelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A., Hosoe, S., Lerman, M. I., Minna, J. D., Maher, E. R., and Latif, F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20: 1509-1518, 2001.
22. Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A. F., Lennan, M. I., Zabarovsky, E., White, M., and Minna, J. D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. (Bethesda), 93: 691-699, 2001.
23. Kuzmin, I., Gillespie, J. W., Protopopov, A., Geil, L., Dreijerink, K., Yang, Y., Vocke, C. D., Duh, F. M., Zabarovsky, E., Minna, J. D., Rhim, J. S., Emmert-Buck, M. R., Linehan, W. M., and Lerman, M. I. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res., 62: 3498-3502, 2002.
24. Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zochbauer-Muller, S., Farinas, A. J., Vakar-Lopez, F., Minna, J. D., Sagalowsky, A., Czerniak, B., and Gazdar, A. F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res., 61: 8659-8663, 2001.
25. Lo, K. W., Kwong, J., Hui, A. B., Chan, S, Y., To, K. F., Chan, A. S., Chow, L. S., Teo, P. M., Johnson, P. J., and Huang, D. P. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res., 61: 3877-3881, 2001.
26. Yoon, J. H., Dammann, R., and Pfeifer, G. P. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int. J. Cancer, 94: 212-217, 2001.
27. van Engeland, M., Roemen, G. M., Brink, M., Pachen, M. M., Weijenberg, M. P., de Bruine, A. P., Arends, J. W., vau den Brandt, P. A., de Goeij, A. F., and Herman, J. G. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 21: 3792-3795, 2002.
28. Tommasi, S., Dammann, R., Jin, S. G., Zhang, X. F., Avruch, J., and Pfeifer, G. P. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene, 21: 2713-2720, 2002.
29. Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J., and Clark, G. J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem., 275: 35669-35672, 2000.
30. Demunter, A., Ahmadian, M. R., Libbrecht, L., Stas, M., Baens, M., Scheffzek, K., Degreef, H., De Wolf-Peeters, C., and van Den Oord, J. J. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res., 61: 4916-4922, 2001.
31. Fujiwara, Y., Chi, D. D., Wang, H., Keleman, P., Morton, D. L., Turner, R., and Hoon, D. S. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res., 59: 1567-1571, 1999.
32. Clark, S. J., Harrison, J., Paul, C. L., and Frommer, M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res., 22: 2990-2997, 1994.
33. Grunau, C., Clark, S. J., and Rosenthal, A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res., 29: e65, 1-7, 2001.
34. Bostick, P. J., Morton, D. L., Turner, R. R., Huynh, K. T., Wang, H. J., Elashoff, R., Essner, R., and Hoon, D. S. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol., 17: 3238-3244, 1999.
35. Schagdarsurengin, U., Gimm, O., Hoang-Vu, C., Dralle, H., Pfeifer, G. P., and Dammann, R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res., 62: 3698-3701, 2002.
36. Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P., Voutilainen, R., Dahia, P., Eng, C., Maher, E. R., and Latif, F. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 20: 7573-7577, 2001.
37. Lusher, M. E., Lindsey, J. C., Farida, L., Pearson, A. D. J., Ellison, D. W., Clifford, S. C. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res., 62: 5906-5911, 2002.
38. Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., and White, M. A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol., 22: 4309-4318, 2002.